# HHS Public Access

# Generation of a Cell-Permeable Cycloheptapeptidyl Inhibitor against Peptidyl-Prolyl Isomerase Pin1

**Walaa Bedewy**[a,b], **Hui Liao**[a], **Nageh A. Abou-Taleb**[b], **Sherif F. Hammad**[b], **Tamer Nasr**[b], and **Dehua Pei**[a]

[a]Department of Chemistry and Biochemistry, The Ohio State University, 484 West 12th Avenue, Columbus, Ohio 43210, United States

[b]Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Helwan University, Egypt

## Abstract

Cyclic peptides are capable of binding and modulating challenging drug targets including protein-protein interactions. However, their lack of membrane permeability prevents their applications against intracellular targets. In this study, we show that it is possible to design a cell-permeable and biologically active cycloheptapeptide inhibitor against intracellular enzyme peptidyl-prolyl isomerase Pin1 by integrating cell-penetrating and target-binding sequences.

## Graphical Abstract

Integration of Pin1-binding and cell-penetrating sequences results in a cell-permeable, biologically active cycloheptapeptide inhibitor against Pin1.



It is estimated that ~80% of therapeutically relevant drug targets are challenging for conventional drug modalities, namely small molecules and biologics.[1] The most prominent examples of undruggable targets are proteins involved in intracellular protein-protein interactions (PPIs), which often possess large, flat binding sites. Small molecules generally do not bind to the flat binding sites with adequate affinity and/or specificity, while biologics

Correspondence to: Dehua Pei.

(e.g., monoclonal antibodies) cannot cross the cell membrane to access these intracellular targets. Despite having well defined active-site pockets, some enzymes may also be challenging drug targets for small molecules. For example, the >100 human protein tyrosine phosphatases (PTPs) remain largely undruggable, because they all share a highly conserved active site structure and it has been difficult to develop inhibitors specific for a given PTP.[2] In addition, the PTP active site is highly positively charged and requires negatively charged species for high-affinity binding, which are generally impermeable to the cell membrane. Another example is the peptidyl-prolyl cis-trans isomerase Pin1, which regulates the levels and functions of phosphoproteins by catalyzing phosphorylation-dependent cis/trans isomerization of peptidyl-prolyl bonds.[3] Because of its critical roles in cell-cycle regulation and increased expression levels and activity in human cancers, Pin1 has been proposed as a potential target for the development of anticancer drugs.[3] Thus far, however, the reported small-molecule Pin1 inhibitors either lack potency and specificity, or is impermeable to the cell membrane due to the presence of negatively charged phosphoamino acid mimetics.[3,4]

Cyclic peptides provide a potential solution for targeting these difficult proteins.[5] Because of their larger sizes than conventional small molecules, cyclic peptides are capable of recognizing flat protein surfaces such as PPI interfaces with antibody-like affinity and specificity.[6] By engaging in additional interactions with the less conserved surfaces outside the active site, cyclic peptides have the ability to differentiate structurally similar enzyme isoforms.[7,8] A major limitation of cyclic peptides, however, is their general lack of membrane permeability. Researchers are currently exploring two different approaches to improving the membrane permeability of cyclic peptides. The first approach involves N-methylation of the peptide backbone and formation of intramolecular hydrogen bonds.[9] An alternative and potentially more general approach is to conjugate the cyclic peptides to a cell-penetrating peptide (CPP).[10] We have previously demonstrated that cyclic peptides of diverse sequences can be rendered cell-permeable by fusing them with a cyclic CPP such as cyclo(FΦRRRRQ) (cFΦR$_4$, where Φ is L-2-naphthylalanine).[8,11,12] Short peptidyl cargos have also been directly inserted into the cyclic CPP ring for cellular uptake (endocyclic delivery).[13,14] The resulting mono- and bicyclic peptides were relatively large molecules, usually consisting of 10–20 amino acids. In this study, we intended to explore the possibility of designing cyclic peptides of smaller sizes as cell-permeable inhibitors against intracellular proteins. Smaller cyclic peptides have considerably greater proteolytic stability, due to greater conformational rigidity, and are less costly to produce than larger ones.

Through screening a combinatorial library, we previously discovered cyclo(D-Ala-Sar-D-pThr-Pip-Nal-Tyr-Gln) (where Sar is sarcosine, D-pThr is D-phosphothreonine, Pip is L-piperidine-2-carboxylic acid, and Nal is L-2-naphthylalanine) as a potent, selective Pin1 inhibitor (Fig. 1 and Table 1, peptide **1**; IC$_{50}$ = 31 nM).[15] SAR studies revealed that only the D-pThr-Pip-Nal motif was required for Pin1 binding. Replacement of D-Ala, Sar, and Tyr with D-Arg and Arg residues resulted in a cycloheptapeptide that retained much of the Pin1 inhibitory activity (IC$_{50}$ = 220 nM) but showed modest cellular entry into HeLa cells (Fig. 1 and Table 1, peptide **2**).[15] We selected peptide **2** as the starting point for optimization of its cellular uptake activities through medicinal chemistry efforts. We first replaced the Gln residue at the D-pThr+4 position (X$^2$) with an arginine and the Arg residue at the D-pThr+3

position ($X^1$) with phenylalanine, 4-fluorophenylalanine (Fpa), tryptophan, or Nal (Table 1, peptides **3–6**). The resulting cyclic peptides resemble cFΦR₄ in structure, each containing two hydrophobic aromatic residues followed by three arginine residues, and were expected to have improved cellular entry.[13,16] Unfortunately, although the incorporation of a second aromatic hydrophobic residue at the D-pThr+3 position ($X^1$) improved the cellular uptake of peptides **3–6** (data not shown), these modifications also reduced their Pin1-binding affinity by 4- to 16-fold, with $IC_{50}$ values of 0.96 – 3.4 μM (Table 1). As a result, peptides **3–6** showed no significant cellular activity on HeLa or other cells.

Our previous study showed that cyclic CPPs of different stereochemical configuration had very different cellular entry capabilities.[16] We further modified the structure of peptide **6** by varying the stereochemical configuration of the D-pThr-1 ($X^4$) and/or D-pThr+3 residues ($X^3$), producing isomers **7** and **8** (Table 1). We also replaced the arginine at the $X^2$ position of peptide **3** with a tryptophan (Table 1, peptide **9**) or switched the side chains of $X^1$ and $X^4$ residues (peptide **10**). However, peptides **7–10** failed to show significant improvement in Pin1 binding affinity or anti-proliferative activity against HeLa cells. Next, we reverted the Nal residue at the D-pThr+3 position of peptide **6** back to arginine to produce peptide **11** (Fig. 2A), because our previous library screening results indicated that among all of the residues tested at this position, arginine was the most preferred amino acid for Pin1 binding.[15] Finally, we varied the stereochemistry of the four arginine residues of peptide **11** to generate stereoisomers **12–14** (Table 1). Interestingly, the four stereoisomers have Pin1 binding affinities that differ by >50-fold, with peptide **11** being most potent ($IC_{50}$ = 245 nM) (Fig. 2B). We posit that the configuration of these arginine residues most likely perturbs the conformation of the D-pThr-Pip-Nal moiety and affects Pin1 binding indirectly, although we cannot rule out the possibility of their engaging in direct electrostatic interactions with the Pin1 protein surface.

Peptide **11** was further evaluated for biological activity. Treatment of HeLa cells (which is a human cervical cancer cell line) for 72 h with peptide **11** resulted in dose-dependent reduction of cancer cell viability as monitored by the MTT assay, apparently due to inhibition of the proliferation of the cancer cells (Fig. 2C). Interestingly, peptide **11** did not reduce the viability of three non-cancerous cell lines tested, including COS-7 (monkey kidney fibroblast), HEK293 (human kidney epithelial), and HS68 (human skin fibroblast) cells. These results are consistent with the previous reports that the Pin1 activity is dispensable for normal cells (since Pin1$^{-/-}$ mice developed normally and had few defects at young ages[17]) but required for cancer cell proliferation.[18] It has been hypothesized that cancer cells may have developed "addiction" to the high Pin1 activities. Liao et al. recently showed that a small-molecule Pin1 inhibitor, all-trans retinoic acid, selectively inhibited the growth of hepatocellular carcinoma cells in vitro and in a mouse xenograft model.[18] To determine whether peptide **11** is capable of inhibiting the intracellular Pin1 activity, HeLa cells were treated with increasing concentrations of peptide **11** (0–10 μM) for 24 h and the intracellular level of promyelocytic leukaemia (PML), a well-established Pin1 substrate which undergoes Pin1-depedent proteasomal degradation,[3,19] was monitored by western blot using a specific anti-PML antibody. Peptide **11** increased the PML protein levels in a dose-dependent manner, reaching a maximal PML level at 5–10 μM peptide **11** (Fig. 2D). As a

comparison, treatment with peptide **2** did not significantly affect the PML level under the same conditions. These data suggest that peptide **11** entered the cytosol of HeLa cells and inhibited the intracellular Pin1 activity. Since peptides **2** and **11** have similar binding affinities to Pin1 (Table 1), the improved cellular activity of peptide **11** (relative to peptide **2**) is likely the result of improved cellular uptake. To test this notion, we replaced the D-pThr residue of peptides **2** and **11** with a D-glutamic acid, added a dipeptide, Asp-Lys, to the D-Glu side chain, and labeled the lysine side chain with fluorescein isothiocyanate (FITC) to give peptides **15** and **16**, respectively (see Fig. S1 in Supplementary Information for detailed structures). The Asp residue was intended to mimic D-pThr by providing a negative charge. Flow cytometry analysis of HeLa cells treated with the labeled peptides (5 μM) for 2 h at 37 °C showed that peptide **16** entered HeLa cells 2.5-fold more efficiently than peptide **15** (Fig. S2). Treatment of HeLa cells with peptide **16** (5 μM) for 2 h at 4 °C resulted in 3-fold lower uptake (or 67% reduction) relative to 37 °C, suggesting that cellular entry of these peptides was mediated by endocytosis followed by endosomal escape.[16] Note that peptide **11** (and **16**) differs from peptide **2** (and **15**) by having an extra arginine (in place of Gln) at the $X^2$ position (Table 1). This additional Arg residue increased the cellular uptake efficiency, apparently without adversely affecting the binding conformation of the D-pThr-Pip-Nal motif. The higher Pin1-binding affinity of peptide **11** relative to peptides **3–6** indicate that the arginine residue at the $X^1$ position contributes significantly to Pin1 binding. This arginine, as well as the Nal residue immediately N-terminal to it, likely play the dual function of cellular entry and Pin1 binding.

## Conclusions

In this work, we demonstrated that it is possible to design cell-permeable and biologically active cyclic peptides as small as a cycloheptapeptide by judicious integration of target-binding and cell-penetrating sequences. Although the mechanism by which these peptides enter cells remains to be defined, their highly hydrophilic nature renders them unlikely to cross the plasma membrane by passive diffusion; instead, their structural similarity to the reported cyclic CPPs and the reduced uptake at 4 °C suggest that they enter cells by endocytosis and subsequently exit from the endosome into the cytosol by a vesicle budding and collapsing mechanism.[16] To the best of our knowledge, these are the smallest biologically active peptides that have been designed to enter cells by non-receptor-mediated endocytic mechanisms. This strategy should be applicable to developing small cyclic peptidyl ligands against other intracellular targets, providing an alternative to the more widely explored N-methylation/intramolecular hydrogen bond (passive diffusion) method.[9]

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

# References

1. Verdine GL, Walensky LD. Clin Cancer Res. 2007; 13:7264. [PubMed: 18094406]

2. Zhang ZY. Acc Chem Res. 2017; 50:122. [PubMed: 27977138]

3. Zhou XZ, Lu KP. Nat Rev Cancer. 2016; 16:463. [PubMed: 27256007]

4. Moore JD, Potter A. Bioorg Med Chem Lett. 2013; 23:4283. [PubMed: 23796453]

5. For recent reviews, see: Cardote TAF, Ciulli A. ChemMedChem. 2016; 11:787. [PubMed: 26563831] Nevola L, Giralt E. Chem Commun. 2015; 51:3302.Dougherty PG, Qian Z, Pei D. Biochem J. 2017; 474:1109. [PubMed: 28298556]

6. (a) Yamagishi Y, Shoji I, Miyagawa S, Kawakami T, Katoh T, Goto Y, et al. Chem Biol. 2011; 18:1562. [PubMed: 22195558] (b) Shi ZD, Wei CQ, Lee K, Liu H, Zhang M, Araki T, Roberts LR, Worthy KM, Fisher RJ, Neel BG, Kelley JA, Yang D, Burke TR. J Med Chem. 2004; 47:2166. [PubMed: 15056012] (c) Zhou H, Liu L, Huang J, Bernard D, Karatas H, Navarro A, Lei M, Wang S. J Med Chem. 2013; 56:1113. [PubMed: 23244744] (d) Duncan, et al. J Med Chem. 2011; 54:3854. [PubMed: 21545152]

7. (a) Furumai R, Komatsu Y, Nishino N, Khochbin S, Yoshida M, Horinouchi S. Proc Natl Acad Sci U S A. 2001; 98:87. [PubMed: 11134513] (b) Angelini A, Cendron L, Chen S, Touati J, Winter G, Zanotti G, Heinis C. ACS Chem Biol. 2012; 7:817. [PubMed: 22304751]

8. Lian W, Jiang B, Qian Z, Pei D. J Am Chem Soc. 2014; 136:9830. [PubMed: 24972263]

9. (a) Bockus AT, Schwochert JA, Pye CR, Townsend CE, Sok V, Bednarek MA, et al. J Med Chem. 2015; 58:7409. [PubMed: 26308180] (b) Matsson P, Doak BC, Over B, Kihlberg J. Adv Drug Deliv Rev. 2016; 101:42. [PubMed: 27067608]

10. (a) Zhang Y, Zhou S, Wavreille AS, DeWille J, Pei D. J Comb Chem. 2008; 10:247. [PubMed: 18257540] (b) Desimmie BA, Humbert M, Lescrinier E, Hendrix J, Vets S, Gijsbers R, et al. Mol Ther. 2012; 20:2064. [PubMed: 22828501]

11. Qian Z, LaRochelle JR, Jiang B, Lian W, Hard RL, Selner N, Luechapanickhul R, Barrios AM, Pei D. Biochemistry. 2014; 53:4034. [PubMed: 24896852]

12. Trinh TB, Upadhyaya P, Qian Z, Pei D. ACS Comb Sci. 2016; 18:75. [PubMed: 26645887]

13. Qian Z, Liu T, Liu Y-Y, Briesewitz R, Barrios AM, Jhiang SM, Pei D. ACS Chem Biol. 2013; 8:423. [PubMed: 23130658]

14. Upadhyaya P, Qian Z, Selner NG, Clippinger SR, Wu Z, Briesewitz R, Pei D. Angew Chem Int Ed. 2015; 54:7602.

15. Liu T, Liu Y, Kao H-Y, Pei D. J Med Chem. 2010; 53:2494. [PubMed: 20180533]

16. Qian Z, Martyna A, Hard RL, Wang J, Appiah-Kubi G, Coss C, Phelps MA, Rossman JS, Pei D. Biochemistry. 2016; 55:2601. [PubMed: 27089101]

17. Fujimori F, Takahashi K, Uchida C, Uchida T. Biochem Biophys Res Commun. 1999; 265:658. [PubMed: 10600477]

18. Liao X-H, Zhang AL, Zheng M, Li M-Q, Chen CP, Xu H, Chu Q-S, Yang D, Lu W, Tsai T-F, Liu H, Zhou XZ, Lu KP. Sci Reports. 2017; 7:43639.

19. Reineke EL, Lam M, Liu O, Liu Y, Stanya KJ, Chang KS, Means AR, Kao HY. Mol Cell Biol. 2008; 28:997. [PubMed: 18039859]

Pin1 Inhibitor A (**1**)
(IC$_{50}$ = 31 nM)
Membrane impermeable

Pin1 Inhibitor F (**2**)
(IC$_{50}$ = 220 nM)
Marginally Permeable

**Fig. 1.**
Structures of previously reported cyclic peptidyl inhibitors against Pin1 (peptides **1** and **2**).

**Fig. 2.**
Biochemical and cellular activities of peptide **11**. (A) Structure of peptide **11**. (B)
Competition for binding to Pin1 (100 nM) between FITC-labeled peptide **1** (50 nM) and
increasing concentrations of unlabelled peptide **11** (0–25 μM) as monitored by fluorescence
anisotropy. (C) Effect of peptide **11** on the viability of HeLa (■), COS-7 (○), HEK293 (●),
and HS68 cells (□) as determined by the MTT assay. (D) Anti-PML western blot analysis of
cell lysates derived from HeLa cells after treatment with increasing concentrations of
peptide **11** (or peptide **2**). β-actin was used as loading control.

**Table 1**

Structures and Pin1 binding affinities of cyclic peptides[a]



| Peptide | Sequence | | | | IC$_{50}$ (nM) |
|---|---|---|---|---|---|
| | X$^1$ | X$^2$ | X$^3$ | X$^4$ | |
| 1 | Tyr | Gln | D-Ala | Sar | 31 ± 3[b] |
| 2 | Arg | Gln | D-Arg | D-Arg | 220 ± 40[b] |
| 3 | Phe | Arg | D-Arg | D-Arg | 1770 ± 280 |
| 4 | Fpa | Arg | D-Arg | D-Arg | 960 ± 210 |
| 5 | Trp | Arg | D-Arg | D-Arg | 1540 ± 270 |
| 6 | Nal | Arg | D-Arg | D-Arg | 3400 ± 810 |
| 7 | Nal | Arg | D-Arg | Arg | 2000 ± 590 |
| 8 | D-Nal | Arg | D-Arg | Arg | >10,000 |
| 9 | Fpa | Trp | D-Arg | Arg | 1810 ± 560 |
| 10 | Arg | D-Arg | Arg | Nal | 1550 ± 330 |
| 11 | Arg | Arg | D-Arg | D-Arg | 245 ± 86 |
| 12 | Arg | D-Arg | Arg | Arg | 5490 ± 160 |
| 13 | Arg | D-Arg | Arg | D-Arg | >10,000 |
| 14 | Arg | D-Arg | D-Arg | Arg | 680 ± 72 |

[a]Data reported are mean ± SD of three independent experiments.

[b]Data from ref. 15.